DiscGenics

DiscGenics is a privately held, late-stage clinical biopharmaceutical company headquartered in Salt Lake City, Utah, developing allogeneic, cell-based regenerative biologic therapies for degenerative diseases of the spine. Its lead candidate, IDCT (rebonuputemcel), is a single-injection allogeneic discogenic progenitor cell therapy for symptomatic mild-to-moderate lumbar degenerative disc disease, manufactured under cGMP from donated adult human intervertebral disc tissue and granted FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company is running a US Phase III program (the PIVOT and CONFIRM studies) alongside a clinical study in Japan. DiscGenics is a therapeutics developer, not a software vendor: it publishes no developer portal, API, SDK or machine-readable specification of any kind.

DiscGenics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Regenerative Medicine, and Cell Therapy.

DiscGenics’ developer surface includes engineering blog, product news, and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyBiopharmaceuticalRegenerative MedicineCell TherapyHealthcareLife SciencesClinical TrialsSpineUtah

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 11.5/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/discgenics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Discgenics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Get Started 2

Portal, sign-up, and the first successful call

ClinicalTrials
ClinicalTrials
 PatientTrialSite
PatientTrialSite

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact
Contact

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 8

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 News
News
 Investors
Investors
 Careers
Careers
 LinkedIn
LinkedIn
 Facebook
Facebook

Scroll for all 8

Source (apis.yml)

apis.yml Raw ↑ 
aid: discgenics
name: DiscGenics
description: 'DiscGenics is a privately held, late-stage clinical biopharmaceutical company headquartered in Salt Lake City,
  Utah, developing allogeneic, cell-based regenerative biologic therapies for degenerative diseases of the spine. Its lead
  candidate, IDCT (rebonuputemcel), is a single-injection allogeneic discogenic progenitor cell therapy for symptomatic mild-to-moderate
  lumbar degenerative disc disease, manufactured under cGMP from donated adult human intervertebral disc tissue and granted
  FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company is running a US Phase III program
  (the PIVOT and CONFIRM studies) alongside a clinical study in Japan. DiscGenics is a therapeutics developer, not a software
  vendor: it publishes no developer portal, API, SDK or machine-readable specification of any kind.'
image: http://static1.squarespace.com/static/59d2b1d812abd948b8707a48/t/59e93fb88a02c760fefcc86b/1774284572317/Discgenics-Logo-White.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/discgenics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Regenerative Medicine
- Cell Therapy
- Healthcare
- Life Sciences
- Clinical Trials
- Spine
- Utah
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/discgenics-domain-security.yml
- type: LLMsTxt
  url: llms/discgenics-llms.txt
- type: Website
  url: https://www.discgenics.com/
- type: About
  url: https://www.discgenics.com/about-us
- type: Blog
  url: https://www.discgenics.com/ceos-blog
- type: News
  url: https://www.discgenics.com/news
- type: Contact
  url: https://www.discgenics.com/contact
- type: TermsOfService
  url: https://www.discgenics.com/terms-of-use
- type: PrivacyPolicy
  url: https://www.discgenics.com/privacy-policy
- type: Investors
  url: https://www.discgenics.com/investors-and-media
- type: Careers
  url: https://www.discgenics.com/about-us#careers
- type: LinkedIn
  url: https://www.linkedin.com/company/discgenics/
- type: Facebook
  url: https://www.facebook.com/DiscGenics
- type: ClinicalTrials
  url: https://clinicaltrials.gov/search?spons=DiscGenics
- type: PatientTrialSite
  url: https://www.dddtrial.com/
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: DiscGenics is a late-stage clinical biopharmaceutical company whose product is an injectable allogeneic cell therapy
    (IDCT/rebonuputemcel), not software — its entire web presence is a bilingual Squarespace marketing site whose 139-URL
    sitemap contains only company, science, pipeline, patient and news pages, with no developer, API or documentation section,
    and no public GitHub organization.
  evidence:
  - url: https://www.discgenics.com/openapi.json
    status: 404
  - url: https://www.discgenics.com/docs
    status: 404
  - url: https://www.discgenics.com/.well-known/agent-card.json
    status: 404
  - url: https://www.dddtrial.com/.well-known/agent-card.json
    status: 404
  - url: https://www.discgenics.com/sitemap.xml
    status: 200
  - url: https://api.github.com/search/users?q=discgenics
    status: 200
  checked: '2026-08-12'